LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Inicio・Lista de Acciones・Kura Oncology Inc
Search

Kura Oncology Inc

Cerrado

SectorSanidad

8.74 -0.91

Compra Fuerte

Precios actualizados 10 jun 2026, 19:59 UTC

ComprarVender

Resumen

Variación precio

24h

Actual

Mínimo

8.69

Máximo

9.1

Métricas clave

By Trading Economics

Ingresos

7.7M

-73M

Ventas

929K

18M

BPA

-0.828

Margen de beneficios

-401.495

Empleados

260

EBITDA

7.4M

-78M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+219.07% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 ago 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-84M

760M

Apertura anterior

9.65

Cierre anterior

8.74

Noticias sobre sentimiento de mercado

By Acuity

100%

0%

315 / 344 Clasificación en Healthcare

Kura Oncology Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

10 jun 2026, 23:36 UTC

Ganancias

Correction to Oracle Reports Higher 4Q Profit Article

DJ

Leer

10 jun 2026, 23:19 UTC

Acciones populares

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

DJ

Leer

10 jun 2026, 23:09 UTC

Principales Movimientos del Mercado

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

DJ

Leer

10 jun 2026, 23:04 UTC

Ganancias

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

DJ

Leer

10 jun 2026, 20:44 UTC

Principales Movimientos del Mercado

Caterpillar Raises Quarterly Dividend 8%

DJ

Leer

10 jun 2026, 23:49 UTC

Adquisiciones, fusiones, absorciones

Elliott: Northern Star Should Take No Options Off The Table

DJ

Leer

10 jun 2026, 23:48 UTC

Adquisiciones, fusiones, absorciones

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

DJ

Leer

10 jun 2026, 23:48 UTC

Adquisiciones, fusiones, absorciones

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

DJ

Leer

10 jun 2026, 23:47 UTC

Charlas de Mercado

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

DJ

Leer

10 jun 2026, 23:47 UTC

Adquisiciones, fusiones, absorciones

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

DJ

Leer

10 jun 2026, 23:46 UTC

Adquisiciones, fusiones, absorciones

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

DJ

Leer

10 jun 2026, 23:38 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

DJ

Leer

10 jun 2026, 23:38 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

DJ

Leer

10 jun 2026, 23:38 UTC

Charlas de Mercado

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

DJ

Leer

10 jun 2026, 23:32 UTC

Charlas de Mercado

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

DJ

Leer

10 jun 2026, 23:20 UTC

Charlas de Mercado

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

DJ

Leer

10 jun 2026, 22:05 UTC

Charlas de Mercado

Correction to Bank of Canada Stays on Hold Market Talk

DJ

Leer

10 jun 2026, 21:57 UTC

Ganancias

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Leer

10 jun 2026, 21:52 UTC

Ganancias

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Leer

10 jun 2026, 21:35 UTC

Ganancias

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Leer

10 jun 2026, 21:22 UTC

Ganancias

Oracle Stock Slides on Increased Capital Spending -- WSJ

DJ

Leer

10 jun 2026, 20:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

DJ

Leer

10 jun 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

DJ

Leer

10 jun 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

DJ

Leer

10 jun 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

DJ

Leer

10 jun 2026, 20:39 UTC

Charlas de Mercado
Ganancias

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

DJ

Leer

10 jun 2026, 20:34 UTC

Ganancias

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Leer

10 jun 2026, 20:33 UTC

Ganancias

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

DJ

Leer

10 jun 2026, 20:33 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

DJ

Leer

10 jun 2026, 20:33 UTC

Charlas de Mercado
Ganancias

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

DJ

Leer

Comparación entre iguales

Cambio de precio

Kura Oncology Inc previsión

Precio Objetivo

By TipRanks

219.07% repunte

Estimación a 12 Meses

Media 28.11 USD  219.07%

Máximo 40 USD

Mínimo 15 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Kura Oncology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

10

Comprar

0

Mantener

0

Vender

De acuerdo con 10 analistas que ofrecen calificaciones bursátiles a para Kura Oncology Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

315 / 344 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.

Otras acciones del sector

LLY

Eli Lilly and Co.

1,136.41

↓-0.5%

JNJ

Johnson and Johnson

238.85

↑ +0.91%

ABBV

AbbVie Inc

225.29

↑ +0.05%

UNH

UnitedHealth Group Inc

407.06

↓-1.28%

MRK

Merck & Co Inc.

119

↓-0.38%
help-icon Live chat